Phaseline

Companies › NextCure

NextCure: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SIM0505 for injection–Phase 1Advanced Solid TumorsFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06792552SIM0505 for injectionPhase 1Advanced Solid TumorsOncologyFeb 2028

From the company's SEC filings

Cash of $15m on 2026-06-30; operating cash outflow about $47m a year; runway about 4 months at that burn, to Oct 2026

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.